
Study finds some medieval Europeans ate horsemeat
The findings challenge prevailing historical narratives that eating horsemeat was considered barbaric or heretical at the time. The study looked at hippophagy, or the eating of horsemeat, and analyzed archaeological evidence from 198 medieval Hungarian settlements, including several in what are now Austria, Croatia, Romania, Serbia and Slovakia.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Natera Announces Launch of ABCSG 61 ("TEODOR"), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer
Study utilizes Signatera to identify HR+, HER2-negative breast cancer patients for de-escalation of neoadjuvant chemotherapy AUSTIN, Texas, July 29, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of the TEODOR trial (Neoadjuvant TrEatment Optimization driven by ctDNA and endOcrine Responsiveness). TEODOR is a Phase II, multicenter, randomized controlled trial (RCT) that aims to replace chemotherapy with endocrine therapy prior to surgery for a subset of women with hormone receptor-positive (HR+), HER2-negative breast cancer, who are endocrine responsive and test negative with Signatera. Sponsored by the Austrian Breast & Colorectal Cancer Study Group (ABCSG), TEODOR expects to enroll approximately 250 patients across 15 sites in Austria. Previous studies have demonstrated that patients who test Signatera-negative at diagnosis and then receive chemotherapy have excellent outcomes, with risk of recurrence at less than 5%. In an effort to reduce pre-operative chemotherapy, which can carry significant side effects, this study is designed to evaluate the efficacy of endocrine therapy compared to chemotherapy in patients who are Signatera-negative. After a four-week course of endocrine therapy, patients who are Signatera-negative and show a favorable endocrine sensitivity as measured by the Ki-67 proliferation index will be randomized to receive either additional endocrine therapy or chemotherapy. The primary endpoint of the study is the rate of neoadjuvant therapy response, assessed via pathological complete response (pCR) and modified Preoperative Endocrine Prognostic Index (PEPI) score across the endocrine therapy and chemotherapy arms of the trial. Secondary endpoints include long-term outcomes such as breast cancer recurrence and overall survival. "TEODOR is designed to examine whether we can use endocrine responsiveness and ctDNA status to optimize systemic therapy in the neoadjuvant setting," said ABCSG President, Michael Gnant, M.D., FACS, FEBS, who serves as professor of surgery, Comprehensive Cancer Center, Medical University of Vienna, and principal investigator of the TEODOR trial. "This study marks a critical step toward more personalized medicine, leveraging the latest technologies to improve patient care." "With the TEODOR trial, our goal is to identify patients who may be able to safely forgo chemotherapy," said Angel Rodriguez, M.D., medical director of oncology at Natera. "We are proud to collaborate with ABCSG on this important trial, and we hope this study will support the role of Signatera in guiding neoadjuvant therapy in breast cancer." About Natera Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit About ABCSG The ABCSG (Austrian Breast & Colorectal Cancer Study Group) is Austria's largest and best-known academic research organization, successfully conducting international clinical trials on breast and colorectal cancer — and, since 2013, also on pancreatic cancer. In addition, ABCSG is increasingly active in translational research. Our goal is to standardize diagnostics, treatment, and follow-up care throughout Austria and to offer patients the best and most up-to-date therapies. Since 1984, approximately 29,000 patients have participated in ABCSG studies worldwide. Multidisciplinarity is key to our global success and has helped improve cure rates and survival. Our clinical trials and translational research projects are conducted transparently and are monitored at every stage by ethics committees, regulatory authorities, and our highly professional and dedicated ABCSG team. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at and View source version on Contacts Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@ Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@ Sign in to access your portfolio


CNN
6 hours ago
- CNN
4,000-year-old handprint found on ancient Egyptian tomb
FacebookTweetLink A 4,000-year-old handprint has been discovered on a clay model used for offerings in an Ancient Egyptian tomb. Researchers from Cambridge University's Fitzwilliam Museum, in the United Kingdom, stumbled upon the imprint while preparing for an exhibition, which is set to open this fall. It was found on the base of a 'soul house,' a building-shaped clay model typically found in burials and said to have provided a place for the soul to live, according to a press release from the museum. The model has an open space at the front where food offerings, like bread, lettuce or an ox's head, could be placed. Dating back to about 2055–1650 BCE, the soul house underwent extensive examinations that revealed how it was made four millennia ago. It showed that the unnamed potter would have first created a framework of wooden sticks for the two-story building, which was then coated with clay. The firing process would have burnt the wood away. The handprint was found underneath the soul house and was most likely formed when the potter moved the model while the clay was still damp and before it was fired in a kiln. 'We've spotted traces of fingerprints left in wet varnish or on a coffin in the decoration, but it is rare and exciting to find a complete handprint underneath this soul house,' said Helen Strudwick, senior Egyptologist at the museum and curator of the exhibition. 'This was left by the maker who touched it before the clay dried,' she said in the release. 'I have never seen such a complete handprint on an Egyptian object before. You can just imagine the person who made this, picking it up to move it out of the workshop to dry before firing.' 'Things like this take you directly to the moment when the object was made and to the person who made it, which is the focus of our exhibition,' Strudwick added. Vast amounts of pottery have survived from the ancient Egyptian period as ceramics were widely used for functional objects and decorative pieces. It was common for pottery containing food and drink to feature in burials. While much is known about ancient Egyptian rulers like Tutankhamun, the stories of those who made some of the many artifacts discovered in their tombs is often overlooked. The ready availability of clay and low value of pottery is likely to have affected social status of potters, according to the museum. The soul house will be on display at the Cambridge museum as part of the 'Made in Ancient Egypt' exhibition, which aims to highlight the stories of artisans like the one who left this handprint behind. It opens on October 3. Discover your world Go beyond the headlines and explore the latest scientific achievements and fascinating discoveries. Sign up for CNN's Wonder Theory science newsletter.
Yahoo
a day ago
- Yahoo
Low Danube waters bring huge mayfly swarms in Budapest
STORY: :: Mayflies swarm the river Danube earlier than usual and in greater numbers :: Budapest, Hungary :: July 23, 2025 :: Gyorgy Kriska, Associate Professor, Eotvos Lorand University 'Since 2012 we have seen huge swarming in those years when the water levels are quite low. We think it is because the sun lights the riverbed more and the algae can breed more and that way the larvae find more food.' :: Researchers put up special blue lights to guide the mayflies, which get confused by city lights :: July 26, 2025 'What our lights are doing is that they keep them here, they don't let them fly above so they keep swarming around the lights, and often a swirl of insects form around the lights, which reaches the surface of the water and they splash into the water. Where the mayflies reach the water they place their eggs there. What we can achieve is that they stay in place over the water and the next generation is saved. They cannot go further up but at least their offspring survive.' :: Mayflies, a protected species in Hungary, live for less than a day after they hatch Hundreds of thousands, sometimes millions, of mayflies engage in a frantic rush to mate and reproduce before they perish within just a few hours. Mayflies live for less than a day after they hatch, and their abundance is closely connected to the health of the Danube. Danube mayflies usually start swarming in August, but this year it began in mid-July, and is expected to last for weeks. Danube mayflies, a protected species, did not swarm for about four decades as the river was too polluted. They returned in 2012 when the Danube became cleaner due to the construction of wastewater treating plants, he added. As mayflies swarm upriver after mating, they can be confused by city lights or the shadows of bridges, causing them to crash on the riverbank instead of laying their eggs in the water. To help them as much as possible, Hungarian researchers installed special blue lights on two bridges. Solve the daily Crossword